文献速递肺血管病与心包/心肌炎

血浆代谢组学揭示tRNA修饰与能量代谢异常与肺动脉高压预后相关

Plasma Metabolomics Implicates Modified Transfer RNAs and Altered Bioenergetics in the Outcomes of Pulmonary Arterial Hypertension.
PubMed 文献 · Circulation · 2016-11-21

该研究采用超高效液相色谱质谱法分析血浆代谢物,发现53种代谢物可区分特发性或遗传性肺动脉高压患者(n=365)与健康对照(n=121),其中20种可区分患者与疾病对照(n=139);62种代谢物与预后相关,36种独立于现有预后标志物;代谢谱与生存强相关,并支持针对翻译调控和能量代谢的靶向治疗研究。

要点

  • 53种血浆代谢物可区分PAH患者与健康对照,校正多重比较后P<7.3e-5。
  • 62种代谢物与PAH预后相关,其中36种独立于已有预后标志物。
  • 代谢谱与生存强相关,部分代谢物纠正与更好结局相关。

核心结论

  • PAH患者血浆代谢谱与生存强相关,应纳入该病的深度表型评估。
  • 结果支持研究针对翻译调控和能量代谢异常的靶向治疗策略。

研究设计与样本

  • 研究采用超高效液相色谱质谱法对血浆代谢物进行全面分析。
  • 研究纳入特发性或遗传性PAH患者365例、健康对照121例及疾病对照139例。

主要发现

  • 53种循环代谢物可区分PAH患者与健康对照,校正多重比较后P<7.3e-5,并校正药物治疗及肝肾损伤等混杂因素。
  • 53种代谢物中的20种也可区分PAH患者与疾病对照(有症状但无肺动脉高压者,n=139)。
  • 62种代谢物在PAH中具有预后价值,其中36种独立于现有预后标志物。
  • tRNA特异性修饰核苷(N2,N2-二甲基鸟苷、N1-甲基肌苷)、三羧酸循环中间产物(苹果酸、富马酸)、谷氨酸、脂肪酸酰基肉碱、色氨酸及多胺代谢物水平升高,类固醇、鞘磷脂及磷脂酰胆碱水平降低,可区分患者与对照。
  • 与死亡风险增加相关性最大的差异代谢物变化最大,且若干代谢物随时间纠正与更好结局相关。

临床怎么用

  • 血浆代谢谱可作为PAH深度表型评估的一部分,用于识别高早死风险患者。
  • 代谢谱有助于识别对治疗反应良好的患者,包括钙通道阻滞剂反应者。
  • 针对翻译调控和能量代谢异常的靶向治疗策略值得进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pulmonary arterial hypertension (PAH) is a heterogeneous disorder with high mortality. METHODS: We conducted a comprehensive study of plasma metabolites using ultraperformance liquid chromatography mass spectrometry to identify patients at high risk of early death, to identify patients who respond well to treatment, and to provide novel molecular insights into disease pathogenesis. RESULTS: Fifty-three circulating metabolites distinguished well-phenotyped patients with idiopathic or heritable PAH (n=365) from healthy control subjects (n=121) after correction for multiple testing (P<7.3e-5) and confounding factors, including drug therapy, and renal and hepatic impairment. A subset of 20 of 53 metabolites also discriminated patients with PAH from disease control subjects (symptomatic patients without pulmonary hypertension, n=139). Sixty-two metabolites were prognostic in PAH, with 36 of 62 independent of established prognostic markers. Increased levels of tRNA-specific modified nucleosides (N2,N2-dimethylguanosine, N1-methylinosine), tricarboxylic acid cycle intermediates (malate, fumarate), glutamate, fatty acid acylcarnitines, tryptophan, and polyamine metabolites and decreased levels of steroids, sphingomyelins, and phosphatidylcholines distinguished patients from control subjects. The largest differences correlated with increased risk of death, and correction of several metabolites over time was associated with a better outcome. Patients who responded to calcium channel blocker therapy had metabolic profiles similar to those of healthy control subjects. CONCLUSIONS: Metabolic profiles in PAH are strongly related to survival and should be considered part of the deep phenotypic characterization of this disease. Our results support the investigation of targeted therapeutic strategies that seek to address the alterations in translational regulation and energy metabolism that characterize these patients.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Rhodes CJ, Ghataorhe P, Wharton J, et al. Plasma Metabolomics Implicates Modified Transfer RNAs and Altered Bioenergetics in the Outcomes of Pulmonary Arterial Hypertension. Circulation. 2016. PMID: 27881557. doi:10.1161/CIRCULATIONAHA.116.024602

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。